Michael Iskedjian

Oakville, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia.

Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia.

Journal: JCO global oncology

Published: October 27, 2020

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis.

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis.

Journal: PharmacoEconomics - open

Published: April 16, 2020

Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.

Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.

Journal: Journal of medical economics

Published: September 14, 2012

Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia.

Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia.

Journal: Journal of medical economics

Published: May 29, 2012

Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses.

Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses.

Journal: Annals of nutrition & metabolism

Published: December 23, 2011

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children.

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children.

Journal: Journal of medical economics

Published: December 17, 2011

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children.

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children.

Journal: Journal of medical economics

Published: December 17, 2011

Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue.

Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue.

Journal: Journal of medical economics

Published: December 06, 2011

Comparison of scores derived from the box score-11 scale and the pain attribute of the health utilities index-3.

Comparison of scores derived from the box score-11 scale and the pain attribute of the health utilities index-3.

Journal: The patient

Published: October 15, 2011

Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis.

Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis.

Journal: The patient

Published: July 20, 2011

Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children.

Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children.

Journal: Current medical research and opinion

Published: October 08, 2010

Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitis.

Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitis.

Journal: Current medical research and opinion

Published: October 08, 2010

Showing 1-12 of 16

Last Updated: 09/26/2026